Febriza A, Idrus H
Malays J Med Sci. 2024; 31(5):143-150.
PMID: 39416736
PMC: 11477468.
DOI: 10.21315/mjms2024.31.5.10.
Sheu M, Pan L, Yang C, Sheehan J, Pan L, You W
Int J Mol Sci. 2023; 24(16).
PMID: 37628850
PMC: 10454604.
DOI: 10.3390/ijms241612664.
Yu H, Zhou W, Zhong Z, Qiu R, Chen G, Zhang P
J Orthop Surg Res. 2022; 17(1):232.
PMID: 35414033
PMC: 9004163.
DOI: 10.1186/s13018-022-03110-8.
Xu X, Chen Y, Liu E, Fu B, Hua J, Chen X
J Immunol Res. 2020; 2020:7165230.
PMID: 33029541
PMC: 7532413.
DOI: 10.1155/2020/7165230.
Han D, Fang Y, Tan X, Jiang H, Gong X, Wang X
J Cell Mol Med. 2020; 24(17):9518-9532.
PMID: 32686306
PMC: 7520283.
DOI: 10.1111/jcmm.15669.
The Janus face of HMGB1 in heart disease: a necessary update.
Raucci A, Di Maggio S, Scavello F, dAmbrosio A, Bianchi M, Capogrossi M
Cell Mol Life Sci. 2018; 76(2):211-229.
PMID: 30306212
PMC: 6339675.
DOI: 10.1007/s00018-018-2930-9.
High-Mobility Group Box-1 and Liver Disease.
Gaskell H, Ge X, Nieto N
Hepatol Commun. 2018; 2(9):1005-1020.
PMID: 30202816
PMC: 6128227.
DOI: 10.1002/hep4.1223.
The potential mechanism of extracellular high mobility group box-1 protein mediated p53 expression in immune dysfunction of T lymphocytes.
Luan Y, Jia M, Zhang H, Zhu F, Dong N, Feng Y
Oncotarget. 2018; 8(68):112959-112971.
PMID: 29348880
PMC: 5762565.
DOI: 10.18632/oncotarget.22913.
Increased expression of damage-associated molecular patterns (DAMPs) in osteoarthritis of human knee joint compared to hip joint.
Rosenberg J, Rai V, Dilisio M, Sekundiak T, Agrawal D
Mol Cell Biochem. 2017; 436(1-2):59-69.
PMID: 28573383
DOI: 10.1007/s11010-017-3078-x.
Damage-associated molecular patterns in the pathogenesis of osteoarthritis: potentially novel therapeutic targets.
Rosenberg J, Rai V, Dilisio M, Agrawal D
Mol Cell Biochem. 2017; 434(1-2):171-179.
PMID: 28474284
PMC: 5671379.
DOI: 10.1007/s11010-017-3047-4.
Respiratory Syncytial Virus Infection Triggers Epithelial HMGB1 Release as a Damage-Associated Molecular Pattern Promoting a Monocytic Inflammatory Response.
Hosakote Y, Brasier A, Casola A, Garofalo R, Kurosky A
J Virol. 2016; 90(21):9618-9631.
PMID: 27535058
PMC: 5068515.
DOI: 10.1128/JVI.01279-16.
Ethyl pyruvate attenuates murine allergic rhinitis partly by decreasing high mobility group box 1 release.
Chen S, Wang Y, Gong G, Chen J, Niu Y, Kong W
Exp Biol Med (Maywood). 2015; 240(11):1490-9.
PMID: 25681468
PMC: 4935307.
DOI: 10.1177/1535370214566563.
Emerging role of HMGB1 in fibrotic diseases.
Li L, Gao J, Li J
J Cell Mol Med. 2014; 18(12):2331-9.
PMID: 25284457
PMC: 4302638.
DOI: 10.1111/jcmm.12419.
The association of HMGB1 gene with the prognosis of HCC.
Xiao J, Ding Y, Huang J, Li Q, Liu Y, Ni W
PLoS One. 2014; 9(2):e89097.
PMID: 24586525
PMC: 3929653.
DOI: 10.1371/journal.pone.0089097.
Inhibition of extracellular HMGB1 attenuates hyperoxia-induced inflammatory acute lung injury.
Entezari M, Javdan M, Antoine D, Morrow D, Sitapara R, Patel V
Redox Biol. 2014; 2:314-22.
PMID: 24563849
PMC: 3926109.
DOI: 10.1016/j.redox.2014.01.013.
Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases.
Lee E, Park J
Genomics Inform. 2014; 11(4):224-9.
PMID: 24465234
PMC: 3897850.
DOI: 10.5808/GI.2013.11.4.224.
Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.
Kikuchi K, Tancharoen S, Ito T, Morimoto-Yamashita Y, Miura N, Kawahara K
Int J Mol Sci. 2013; 14(9):18899-924.
PMID: 24065095
PMC: 3794813.
DOI: 10.3390/ijms140918899.
HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development.
Kikuchi K, Uchikado H, Miura N, Morimoto Y, Ito T, Tancharoen S
Exp Ther Med. 2012; 2(5):767-770.
PMID: 22977572
PMC: 3440833.
DOI: 10.3892/etm.2011.310.
Poly(ADP-ribosyl)ation of high mobility group box 1 (HMGB1) protein enhances inhibition of efferocytosis.
Davis K, Banerjee S, Friggeri A, Bell C, Abraham E, Zerfaoui M
Mol Med. 2011; 18:359-69.
PMID: 22204001
PMC: 3356430.
DOI: 10.2119/molmed.2011.00203.
Microglial activation in stroke: therapeutic targets.
Yenari M, Kauppinen T, Swanson R
Neurotherapeutics. 2010; 7(4):378-91.
PMID: 20880502
PMC: 5084300.
DOI: 10.1016/j.nurt.2010.07.005.
